Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/CD3 bispecific antibody GNR-084

A bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 bispecific antibody GNR-084 binds to both the CD3 antigen on T cells and the CD19 antigen expressed on tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19/anti-CD3 bispecific antibody GNR-084
anti-CD19/CD3 bispecific T-cell engager antibody GNR-084
CD19 x CD3 bispecific antibody GNR-084
Code name:GNR 084
GNR-084
GNR084
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search